¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ 8x" d/D  
a% !XLyq  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© zl\#n:|  
8:% R |b  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©  ?~.&Y  
fYy.>m+P1  
1.Co-stimulators (or co-stimulating molecules) ^W D$ gd  
}^[@m#  
2.NK-kB A232"p_  
jyhzLu  
3.Immunoglobulin superfamily W~3tQ!  
(OB8vTRXP  
4.antigen-presenting cell (APC) pXv[]v  
Jt6J'MOq  
5.death domain 3 \r@f_p  
0@lC5-=  
6.CCR and CXCR su FOc  
"5:f{GfO#v  
7.Lectin (or mitogen) K<6x4ha  
Lc<xgN+cJ  
8.Clusters of differentiation, CD) *"FLkC4  
%:KV2GP  
9.B7 family !`[I>:Ex  
_F@p53WE  
10.Cytotoxic T lymphocyte, CTL) :ZS 8Zm"  
6^O?p2xpo  
11.IL-15 and IL-15 receptor (IL-15R) Hu8atlpo  
*}ee"eHs  
12.MHC restriction ^FM9} t/U,  
@:+n6  
13.Affinity-chromatography ynZ[c8.  
C6UMc} 9h  
14.Cyctosprin A, CsA '$h @  
 OI_/7@L  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) BX(d"z b<  
N~; khS]  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© `JWYPsWk  
Eqm v`Z [_  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 ;q,)NAr&  
e*2&s5 #RT  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ Mj B< \g>  
$wYuH9(  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ I0w@ S7  
vN,}aV2nq  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 5<O61Lgx  
ok3  
ÃâÒßѧרҵ£º ECS<l*i57&  
adO!Gs9f?  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ RZd4(7H=q  
g/ l0}%  
Ïû»¯ÄÚ¿Æ£º o7Cnyy#:  
)-.Cne;n  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ fmnRUN=  
BK(pJNBh  
ѪҺ²¡Ñ§×¨Òµ£º }+{*, z  
@cu}3>  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»